Modality
Gene Therapy
MOA
TNFi
Target
TIGIT
Pathway
RAS/MAPK
MMCholangiocarcinomaALL
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ Jun 2025
Phase 1Current
NCT05397636
336 pts·MM
2020-01→2025-06·Completed
336 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0110mo agoInterim· MM
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1
Complet…
Catalysts
Interim
2025-06-01 · 10mo ago
MM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05397636 | Phase 1 | MM | Completed | 336 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |